文献速递药物不良反应与药物警戒

乌干达青蒿素类抗疟治疗药物不良反应负担的主动随访研究

The Burden of Adverse Drug Reactions Due to Artemisinin-Based Antimalarial Treatment in Selected Ugandan Health Facilities: An Active Follow-Up Study.
PubMed 文献 · Drug Saf · 2018-01-01

该研究在乌干达三个地区对782例无并发症疟疾患者进行主动随访,发现青蒿素类抗疟治疗相关药物不良反应(ADR)患病率为22.5%(176/782),最常见为全身乏力、头痛和头晕。女性、城市居民及有合并症者发生ADR的风险显著更高,提示需针对这些风险因素优化治疗并加强ADR监测。

要点

  • 青蒿素类抗疟治疗ADR患病率达22.5%,以全身乏力、头痛、头晕多见。
  • 女性、城市居民及有合并症者发生ADR风险显著升高。
  • 实施疟疾治疗政策时应加强ADR密切监测并考虑上述风险因素。

核心结论

  • 青蒿素类抗疟治疗的ADR负担较高,女性、城市居民及有合并症者风险更高,需在优化治疗时予以考虑。

研究设计与样本

  • 2017年4月至7月在乌干达Iganga、Mayuge和Kampala地区开展主动随访研究,纳入782例无并发症疟疾患者,中位年龄22岁,58.6%为女性,97%来自公共卫生机构。

主要发现

  • ADR患病率为22.5%(176/782),共报告245例次ADR,最常见为全身乏力(24%)、头痛(13%)和头晕(11%)。
  • 女性发生ADR的风险高于男性(aOR 1.8,95%CI 1.1-2.9)。
  • 城市居民发生ADR的风险高于农村居民(aOR 9.9,95%CI 5.4-17.9)。
  • 有合并症者发生ADR的风险高于无合并症者(aOR 7.4,95%CI 4.4-12.3)。

临床怎么用

  • 对女性、城市居民及有合并症的患者应加强ADR监测与随访。
  • 在疟疾治疗政策实施中应纳入主动的药物警戒措施以优化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Uganda has rapidly increased access to antimalarial medicines in an effort to address the huge malaria disease burden. Pharmacovigilance information is important to guide policy decisions. OBJECTIVES: The purpose of this study was to establish the burden of adverse drug reactions (ADRs) and associated risk factors for developing ADRs to artemisinin-based antimalarial treatment in Uganda. METHODS: An active follow-up study was conducted between April and July 2017 in a cohort of patients receiving treatment for uncomplicated malaria in the Iganga, Mayuge, and Kampala districts. RESULTS: A total of 782 patients with a median age of 22 years (58.6% females) were recruited into this study, with the majority recruited from public health facilities (97%). Diagnostic tests before treatment were performed for 76% of patients, and 97% of patients received artemether/lumefantrine. The prevalence of ADRs was 22.5% (176/782); however, the total number of ADRs was 245 since some patients reported more than one ADR. The most commonly reported reactions were general body weakness (24%), headache (13%), and dizziness (11%). Women were more likely to develop an ADR (adjusted odds ratio [aOR] 1.8, 95% confidence interval [CI] 1.1-2.9), urban dwellers were more likely to develop an ADR than rural residents (aOR 9.9, 95% CI 5.4-17.9), and patients with comorbidities were more likely to develop an ADR than those without (aOR 7.4, 95% CI 4.4-12.3). CONCLUSION: The burden of ADRs is high among women and in patients from urban settings and those with comorbidities. Such risk factors need to be considered in order to optimise therapy. Close monitoring of ADRs is key in implementation of the malaria treatment policy.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Ndagije HB, Nambasa V, Manirakiza L, et al. The Burden of Adverse Drug Reactions Due to Artemisinin-Based Antimalarial Treatment in Selected Ugandan Health Facilities: An Active Follow-Up Study. Drug Saf. 2018. PMID: 29627926. doi:10.1007/s40264-018-0659-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。